XML 30 R16.htm IDEA: XBRL DOCUMENT v3.20.2

Note 1 - Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2020

Notes Tables

Debt Securities, Available-for-sale [Table Text Block]

			June 30, 2020
			Amortized Cost				Accrued Interest				Gross Unrealized Gains				Gross Unrealized Losses				Estimated Fair Value
Obligations of the U.S. Government and its agencies			$	14,991			$	-			$	-			$	-			$	14,991
Certificates of deposit				938				3				3				-				944
Total investments			$	15,929			$	3			$	3			$	-			$	15,935

		December 31, 2019
		Amortized Cost				Accrued Interest				Gross Unrealized Gains				Gross Unrealized Losses				Estimated Fair Value
Obligations of U.S. Government and its agencies		$	10,488			$	50			$	23			$	-			$	10,561
Corporate debt securities			9,742				59				10				(1	)			9,810
Certificates of deposit			1,669				7				7				-				1,683
Total investments		$	21,899			$	116			$	40			$	(1	)		$	22,054

Schedule of Receivables from Collaborations [Table Text Block]

						June 30, 2020
		Billed				Unbilled				Total
U.S. Department of Health and Human Services		$	19			$	2,253			$	2,272
Shionogi & Co. Ltd.			1,683				-				1,683
Mundipharma International Holdings Limited			35				-				35
Seqirus UK Limited			7				-				7
Total receivables		$	1,744			$	2,253			$	3,997

						December 31, 2019
		Billed				Unbilled				Total
U.S. Department of Health and Human Services		$	1,353			$	15,023			$	16,376
Shionogi & Co. Ltd.			1,336				4				1,340
Green Cross Corporation			2,924				8				2,932
Mundipharma International Holdings Limited			56				-				56
Seqirus UK Limited			1,091				351				1,442
Total receivables		$	6,760			$	15,386			$	22,146

Disaggregation of Revenue [Table Text Block]

		Three Months								Six Months
		2020				2019				2020				2019
Product sales		$	—			$	—			$	218			$	1,679
Royalty revenue			44				696				1,989				3,018
Collaborative and other research and development revenues:
U.S. Department of Health and Human Services			2,545				752				4,152				2,638
Torii Pharmaceutical Co., Ltd.			282				—				1,335				—
Total collaborative and other research and development revenues			2,827				752				5,487				2,638
Total revenues		$	2,871			$	1,448			$	7,694			$	7,335

X

- Definition

Tabular disclosure representing receivables from collaborations.

+ References

No definition available.

+ Details

Name:	bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock
Namespace Prefix:	bcrx_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928

+ Details

Name:	us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration